{"denoms":[{"counts":[{"groupId":"BG000","value":"6"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"2"},{"groupId":"BG003","value":"8"}],"units":"Participants"}],"groups":[{"description":"c-MET high (\\> 50%), RON null (0-9%)\n\nCrizotinib: All arms will receive crizotinib.","id":"BG000","title":"Cohort 1"},{"description":"c-MET + (10-100%), RON + (10-100%)\n\nCrizotinib: All arms will receive crizotinib.","id":"BG001","title":"Cohort 2"},{"description":"c-MET null (0-9%), RON + (10-100%)\n\nCrizotinib: All arms will receive crizotinib.","id":"BG002","title":"Cohort 3"},{"description":"Total of all reporting groups","id":"BG003","title":"Total"}],"measures":[{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","lowerLimit":"53","upperLimit":"77","value":"60"},{"groupId":"BG002","lowerLimit":"64","upperLimit":"79","value":"71.5"},{"groupId":"BG003","lowerLimit":"53","upperLimit":"79","value":"62"}]}]}],"dispersionType":"FULL_RANGE","paramType":"MEDIAN","title":"Age, Continuous","unitOfMeasure":"years"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"2"},{"groupId":"BG002","value":"0"},{"groupId":"BG003","value":"2"}],"title":"Female"},{"measurements":[{"groupId":"BG000","value":"4"},{"groupId":"BG002","value":"2"},{"groupId":"BG003","value":"6"}],"title":"Male"}]}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Sex: Female, Male","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG002","value":"0"},{"groupId":"BG003","value":"0"}],"title":"Hispanic or Latino"},{"measurements":[{"groupId":"BG000","value":"6"},{"groupId":"BG002","value":"2"},{"groupId":"BG003","value":"8"}],"title":"Not Hispanic or Latino"},{"measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG002","value":"0"},{"groupId":"BG003","value":"0"}],"title":"Unknown or Not Reported"}]}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Ethnicity (NIH/OMB)","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG002","value":"0"},{"groupId":"BG003","value":"0"}],"title":"American Indian or Alaska Native"},{"measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG002","value":"0"},{"groupId":"BG003","value":"0"}],"title":"Asian"},{"measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG002","value":"0"},{"groupId":"BG003","value":"0"}],"title":"Native Hawaiian or Other Pacific Islander"},{"measurements":[{"groupId":"BG000","value":"1"},{"groupId":"BG002","value":"0"},{"groupId":"BG003","value":"1"}],"title":"Black or African American"},{"measurements":[{"groupId":"BG000","value":"5"},{"groupId":"BG002","value":"2"},{"groupId":"BG003","value":"7"}],"title":"White"},{"measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG002","value":"0"},{"groupId":"BG003","value":"0"}],"title":"More than one race"},{"measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG002","value":"0"},{"groupId":"BG003","value":"0"}],"title":"Unknown or Not Reported"}]}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Race (NIH/OMB)","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"6"},{"groupId":"BG002","value":"2"},{"groupId":"BG003","value":"8"}]}],"title":"United States"}],"paramType":"NUMBER","title":"Region of Enrollment","unitOfMeasure":"participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"5"},{"groupId":"BG002","value":"1"},{"groupId":"BG003","value":"6"}],"title":"Bladder"},{"measurements":[{"groupId":"BG000","value":"1"},{"groupId":"BG002","value":"1"},{"groupId":"BG003","value":"2"}],"title":"Other"}]}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Primary Tumor Site","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"4"},{"groupId":"BG002","value":"0"},{"groupId":"BG003","value":"4"}],"title":"0"},{"measurements":[{"groupId":"BG000","value":"2"},{"groupId":"BG002","value":"2"},{"groupId":"BG003","value":"4"}],"title":"1"}]}],"description":"Measure Description: ECOG Scale of Performance Status, developed by the Eastern Cooperative Oncology Group, where 0 indicates subject is fully active, able to carry on all pre-disease performance without restriction and where 1 indicates subject is restricted in physically strenuous activity but ambulatory and able to carry out work of a light or sedentary nature, e.g., light house work, office work.","paramType":"COUNT_OF_PARTICIPANTS","title":"ECOG at Baseline","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG002","value":"1"},{"groupId":"BG003","value":"1"}],"title":"0%"},{"measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG002","value":"1"},{"groupId":"BG003","value":"1"}],"title":"1 - 9%"},{"measurements":[{"groupId":"BG000","value":"2"},{"groupId":"BG002","value":"0"},{"groupId":"BG003","value":"2"}],"title":"51 - 75%"},{"measurements":[{"groupId":"BG000","value":"4"},{"groupId":"BG002","value":"0"},{"groupId":"BG003","value":"4"}],"title":">75%"}]}],"description":"c-MET protein expression was assessed by immunohistochemistray as percent of tumor cells staining positive.","paramType":"COUNT_OF_PARTICIPANTS","title":"c-MET Expression, %","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"2"},{"groupId":"BG002","value":"0"},{"groupId":"BG003","value":"2"}],"title":"0%"},{"measurements":[{"groupId":"BG000","value":"4"},{"groupId":"BG002","value":"0"},{"groupId":"BG003","value":"4"}],"title":"1 - 9%"},{"measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG002","value":"2"},{"groupId":"BG003","value":"2"}],"title":">75%"}]}],"description":"RON protein expression was assessed by immunohistochemistray as percent of tumor cells staining positive.","paramType":"COUNT_OF_PARTICIPANTS","title":"RON Expression, %","unitOfMeasure":"Participants"}],"populationDescription":"Note, there were no subjects enrolled to cohort 2 as no subjects were enrolled who were c-MET + and RON+. Therefore, no baseline results are available for Cohort 2."}